U.S. Huntingtons Disease Treatment Market Size & Outlook
Related Markets
U.S. huntingtons disease treatment market highlights
- The U.S. huntingtons disease treatment market generated a revenue of USD 169.7 million in 2024 and is expected to reach USD 632.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 23.8% from 2025 to 2030.
- In terms of segment, symptomatic treatment was the largest revenue generating treatment in 2024.
- Symptomatic Treatment is the most lucrative treatment segment registering the fastest growth during the forecast period.
Huntingtons disease treatment market data book summary
| Market revenue in 2024 | USD 169.7 million |
| Market revenue in 2030 | USD 632.3 million |
| Growth rate | 23.8% (CAGR from 2025 to 2030) |
| Largest segment | Symptomatic treatment |
| Fastest growing segment | Symptomatic Treatment |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Symptomatic Treatment |
| Key market players worldwide | H. Lundbeck AS Class A, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, U.S. accounted for 33.9% of the global huntingtons disease treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. huntingtons disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 89.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Huntingtons Disease Treatment Market Scope
Huntingtons Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. huntingtons disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 128.29% in 2024. Horizon Databook has segmented the U.S. huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. Huntington’s disease treatment market is anticipated to witness significant growth over the forecast period owing to rising prevalence of the disease coupled with product development for HD treatment. According to National Organization for Rare Disorders, around 30,000 patients are affected with HD in the U.S., and the disease generally develops in population aged 30 to 50.
Research grants by nonprofit organizations, such as Huntington’s Disease Society of America, for development of disease treatment are expected to support market growth. The availability of products such as Xenazine and Austedo by H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., respectively, in the region is expected to contribute to market growth.
In April 2017, Teva Pharmaceutical Industries Ltd. received the U.S. FDA approval for launch of Austedo (deutetrabenazine) for treating chorea in patients suffering from HD. Chorea affects around 90% of HD patients, which is characterized by sudden involuntary writhing movements.
Reasons to subscribe to U.S. huntingtons disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. huntingtons disease treatment market databook
-
Our clientele includes a mix of huntingtons disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. huntingtons disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. huntingtons disease treatment market size, by treatment, 2018-2030 (US$M)
U.S. Huntingtons Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
